Revisiting G-CSF Support for Hematologic Recovery after Autologous Transplantation in AML Patients

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients

“…Hematologic recovery after ASCT using plerixafor and G‐CSF stimulation for collection of CD34 + PBSC is of obvious interest. Neutrophil recovery >0.5 G/L after ASCT occurred after a median of 12 days, and, thus, was identical as in a previous large study in AML patients receiving G‐CSF only 12 . Platelet recovery >20 G/L seemed prolonged in plerixafor mobilized AML patients, with a median of 45 days versus 16 days in G‐CSF‐only mobilized patients in our previous series 12 .…”

“…Neutrophil recovery >0.5 G/L after ASCT occurred after a median of 12 days, and, thus, was identical as in a previous large study in AML patients receiving G‐CSF only 12 . Platelet recovery >20 G/L seemed prolonged in plerixafor mobilized AML patients, with a median of 45 days versus 16 days in G‐CSF‐only mobilized patients in our previous series 12 . Possibly, this delayed platelet recovery in plerixafor mobilized AML patients reflects the background of primary mobilization failure and a poor stem cell pool in these particular patients.…”

“…Whereas available data suggest that ASCT with PBSC can be recommended to distinct subgroups of AML patients, there is little information on the mobilization failure rate and on rescue strategies for AML patients with a failed attempt of autologous PBSC collection. 12,13 In AML patients, chemosensitivity of colony-forming units of granulocytes and monocytes derived from BM cells were described to correlate inversely with the peripheral maximum CD34 + cells peak during SC mobilization. 14 Plerixafor, a small-molecule inhibitor of the CXCR4 chemokine receptor, has been approved in combination with G-CSF for PBSC mobilization for lymphoma and myeloma patients.…”